SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...
DUBLIN, June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced that it has entered into a definitive agreement to sell its remaining royalty ...
Theravance Biopharma TBPH announced that it has entered into an agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK plc GSK for $225 million in cash. Theravance ...
After years of picking up royalties on GSK’s asthma and COPD inhaler Trelegy, Theravance Biopharma is opting to sell its remaining financial interest to GSK in exchange for a cash reward of $225 ...
Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results